Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen
** The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's under the brand name Kisunla, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients
** Eli Lilly shares up 0.5% at $911.41 premarket
EXPECTED APPROVAL WITH LABEL IN LINE
** Jefferies ("buy", PT:$906.71) says despite having similar labels, it expects Biogen/Eisai's BIIB.O, 4523.T Leqembi to retain a dominant share of the market because it has a somewhat better risk-benefit profile
** BMO Capital Markets ("outperform", PT: $914.37) says it estimates peak Kisunla sales to reach $7.1 bln, meaningfully diversifying the company's revenue in the second half of the decade
** Approval of Kisunla is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure - BMO
** Cantor Fitzgerald ("overweight", PT: $885) calls LLY a "marketing machine" adding that Kisunla helps diversify sales into an area with blockbuster potential
** In a note on Leqembi, brokerage William Blair says a major debate will be whether to select it as an option for more traditional chronic therapy, or Kisunla for the potential option of stopping therapy if plaque removal is achieved
** Truist Securities ("buy", PT: $914.37) says Kisunla's differentiated profile could potentially lower overall treatment costs
Reporting by Christy Santhosh
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
